◎ Sugi Atlas

Atlas / Drug / Pergolide

Pergolide

drug
On this page

Also known as PergolidaSID26754330SID26754331SID90341767SID104171354Pergolide mesylate

Summary

Pergolide (CHEMBL531) is an approved small-molecule antiparkinson drug (ATC N04BC02) targeting HTR6, HTR7, and HTR1A; indicated across 3 conditions including parkinson disease and cocaine dependence.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: N04BC02
  • Targets: 16 (HTR6, HTR7, HTR1A…)
  • Indications: 3 conditions
  • Clinical trials: 8
  • Chemistry: 314.5 Da · C19H26N2S

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL531
NamePergolide
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID47811
ChEBICHEBI:63617
ATCN04BC02
Molecular formulaC19H26N2S
Molecular weight314.5
InChIKeyYEHCICAEULNIGD-MZMPZRCHSA-N

SMILES: CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC

IUPAC name: (6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline

ChEBI definition: A diamine that is ergoline in which the β-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson’s disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.

Pharmacological roles (ChEBI): antiparkinson drug, dopamine agonist.

Also known as: Pergolida, Pergolide, pergolide, SID26754330, SID26754331, SID90341767, SID104171354, PERGOLIDE, Pergolide mesylate

Parent form; salt/anhydrous children: CHEMBL1275

Patent coverage: 5,530 distinct patent families (23,128 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 23,093 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
HTR65-HT6 receptorFull agonist7.50.2%P50406
HTR75-HT7 receptorFull agonist90.8%P34969
HTR1A5-HT1A receptorPartial agonist8.70%P08908
DRD1D1 receptorFull agonist6.50%P21728
DRD2D2 receptorFull agonist7.60%P14416
DRD3D3 receptorPartial agonist8.30%P35462
DRD4D4 receptorPartial agonist7.20%P21917
DRD5D5 receptorFull agonist7.50%P21918
ADRA2Aα2A-adrenoceptorPartial agonist7.30.1%P08913
ADRA2Bα2B-adrenoceptorPartial agonist7.50.2%P18089
ADRA2Cα2C-adrenoceptorAgonist7.20%P18825
HTR1B5-HT1B receptorFull agonist6.60.2%P28222
HTR1D5-HT1D receptorPartial agonist7.90%P28221
HTR2A5-HT2A receptorFull agonist8.10%P28223
HTR2B5-HT2B receptorFull agonist8.20.4%P41595
HTR2C5-HT2C receptorPartial agonist6.50%P28335

Broader ChEMBL bioactivity targets: 38 (assay-derived). Sample: 4’-phosphopantetheinyl transferase ffp, 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Adrenergic receptor alpha-1, Alpha-2C adrenergic receptor, Histamine H2 receptor, Alpha-2B adrenergic receptor, D(1A) dopamine receptor, Adrenergic receptor alpha-2, Dopamine receptor.

Bioactivity

ChEMBL activities: 105 potent at pChembl ≥ 5 of 111 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
DRD29.45EC500.35nMCHEMBL_ACT_16879808
DRD29.21Ki0.62nMCHEMBL_ACT_25553902
DRD39.07Ki0.85nMCHEMBL_ACT_1500317
P611699Ki1nMCHEMBL_ACT_412896
P189018.8IC501.6nMCHEMBL_ACT_1260057
P611698.8IC501.6nMCHEMBL_ACT_325683
HTR1A8.74Ki1.8nMCHEMBL_ACT_412895
DRD38.74Ki1.83nMCHEMBL_ACT_7727836
P190208.62IC502.41nMCHEMBL_ACT_12456226
P189018.51IC503.1nMCHEMBL_ACT_1092838
P189018.51IC503.1nMCHEMBL_ACT_825081
HTR2A8.41Ki3.9nMCHEMBL_ACT_7729974
DRD28.4Ki4nMCHEMBL_ACT_118891
DRD38.4Ki4nMCHEMBL_ACT_118892
HTR1A8.4Ki4nMCHEMBL_ACT_118893
P611698.4Kd4nMCHEMBL_ACT_219411
DRD28.4Ki4nMCHEMBL_ACT_25917656
DRD38.4Ki4nMCHEMBL_ACT_25917670
P189018.39IC504.1nMCHEMBL_ACT_1260059
P190208.37EC504.31nMCHEMBL_ACT_12456198
HTR2A8.31AC504.9nMCHEMBL_ACT_25226713
P190208.29IC505.12nMCHEMBL_ACT_12456215
DRD38.27IC505.39nMCHEMBL_ACT_7727835
P190208.25IC505.59nMCHEMBL_ACT_12456253
HTR1A8.24Ki5.7nMCHEMBL_ACT_25917694
P190208.23IC505.85nMCHEMBL_ACT_12456239
DRD48.21Ki6.2nMCHEMBL_ACT_25917679
P611698.11EC507.86nMCHEMBL_ACT_12456208
HTR2B8.08AC508.4nMCHEMBL_ACT_25164298
P193278.07Ki8.47nMCHEMBL_ACT_7729970

Target pathways

Aggregated over 16 target gene(s): HTR6, HTR7, HTR1A, DRD1, DRD2, DRD3, DRD4, DRD5, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C.

Top Reactome pathways

24 total, by targets touching each:

PathwayTargetsGenes
Signal Transduction11ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
Signaling by GPCR11ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
Class A/1 (Rhodopsin-like receptors)11ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
Amine ligand-binding receptors11ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
GPCR ligand binding11ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
GPCR downstream signalling10ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
Serotonin receptors8HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
G alpha (i) signalling events7ADRA2A, ADRA2B, ADRA2C, DRD3, DRD4, HTR1B, HTR1D
Dopamine receptors5DRD1, DRD2, DRD3, DRD4, DRD5
G alpha (s) signalling events4DRD1, DRD5, HTR6, HTR7
Hemostasis3ADRA2A, ADRA2B, ADRA2C
Adrenoceptors3ADRA2A, ADRA2B, ADRA2C
Adrenaline signalling through Alpha-2 adrenergic receptor3ADRA2A, ADRA2B, ADRA2C
G alpha (q) signalling events3HTR2A, HTR2B, HTR2C
G alpha (z) signalling events3ADRA2A, ADRA2B, ADRA2C
Platelet activation, signaling and aggregation3ADRA2A, ADRA2B, ADRA2C
Platelet Aggregation (Plug Formation)3ADRA2A, ADRA2B, ADRA2C
Metabolism2ADRA2A, ADRA2C
Integration of energy metabolism2ADRA2A, ADRA2C
Metabolism of proteins2ADRA2A, ADRA2C
Adrenaline,noradrenaline inhibits insulin secretion2ADRA2A, ADRA2C
Regulation of insulin secretion2ADRA2A, ADRA2C
Surfactant metabolism2ADRA2A, ADRA2C
RHOBTB3 ATPase cycle1HTR7

Dominant GO biological processes

GO termTargets
signal transduction16
G protein-coupled receptor signaling pathway16
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger10
chemical synaptic transmission10
G protein-coupled serotonin receptor signaling pathway7
intracellular calcium ion homeostasis7
positive regulation of MAPK cascade6
adenylate cyclase-activating G protein-coupled receptor signaling pathway5
response to xenobiotic stimulus5
behavioral response to cocaine5
phospholipase C-activating dopamine receptor signaling pathway5
synaptic transmission, dopaminergic5
response to cocaine5
adenylate cyclase-modulating G protein-coupled receptor signaling pathway4
vasoconstriction4

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
Parkinson disease4MONDO:0005180MONDO:0005180
cocaine dependence3MONDO:0005186EFO:0002610
drug dependence2MONDO:0005303EFO:0003890

Clinical trials

Total trials: 8.

Phase distribution

PhaseTrials
Not specified5
PHASE22
PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00000248PHASE3COMPLETEDDose Response Trial of Pergolide for Cocaine Dependence - 1
NCT00000215PHASE2COMPLETEDIV Cocaine Abuse: A Laboratory Model - 4
NCT00000269PHASE2COMPLETEDPergolide Treatment for Substance Abusers - 4
NCT00004433Not specifiedCOMPLETEDRandomized Study of Pergolide in Children With Tourette Syndrome
NCT00197483Not specifiedSUSPENDEDEffective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia
NCT00252044Not specifiedUNKNOWNPergolide for Cognitive Symptoms in Schizotypal Personality Disorder
NCT00624741Not specifiedNO_LONGER_AVAILABLECompassionate Use Study of Pergolide in Patients With Parkinson’s Disease
NCT01066403Not specifiedCOMPLETEDAdjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

990 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
BREXPIPRAZOLEChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
DIHYDROERGOTAMINEChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
ARIPIPRAZOLEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
CARIPRAZINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
RISPERIDONEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
CLOZAPINEChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR6, HTR7
OLANZAPINEChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR6, HTR7
TEGASERODChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
IMIPRAMINEChEMBLPhase 4 (approved)ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
NEFAZODONEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
AMOXAPINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
CHLORPROMAZINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
DOXEPINChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
FLUPHENAZINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
HALOPERIDOLChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
KETANSERINChEMBLPhase 4 (approved)ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
LOXAPINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
MIANSERINChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
PROMAZINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
PENFLURIDOLChEMBLPhase 2ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
RITANSERINChEMBLPhase 2ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR2A, HTR2C, HTR6, HTR7
PALIPERIDONEChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1B, HTR1D, HTR2A, HTR2C, HTR7
PRAMIPEXOLEChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR2A, HTR2B, HTR7
AMITRIPTYLINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6
ASTEMIZOLEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
AZELASTINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
CARVEDILOLChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
ERGOTAMINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6
KETOTIFENChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD5, HTR1B, HTR2A, HTR2B, HTR2C, HTR6, HTR7
QUETIAPINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
SERTINDOLEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR6
THIORIDAZINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
THIOTHIXENEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
ZIPRASIDONEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
SPIPERONEChEMBLPhase 2ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
PyrazinamidePubChemApprovedADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
DESLORATADINEChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6
APOMORPHINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C
ASENAPINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6
BROMOCRIPTINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6
CYPROHEPTADINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
EBASTINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6
ILOPERIDONEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6
MAPROTILINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6
METHYSERGIDEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
PIMOZIDEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6
PROCHLORPERAZINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6
PROMETHAZINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6
SILODOSINChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2B, HTR7
SUNITINIBChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6
VILAZODONEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2B, HTR6, HTR7
LISURIDEChEMBLPhase 3ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6
YOHIMBINEChEMBLPhase 3ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR6
METERGOLINEChEMBLPhase 2ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7
NIGULDIPINEChEMBLPhase 2ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD5, HTR1A, HTR1B, HTR2C, HTR6, HTR7
SPIRAMIDEChEMBLPhase 2ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR1D, HTR2A, HTR2B, HTR6, HTR7
CINACALCETChEMBL + PubChemPhase 4 (approved)ADRA2B, ADRA2C, DRD2, DRD3, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
FidaxomicinChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
PropoxypheneChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
BENPERIDOLChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot